GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation
Phase 2
Completed
- Conditions
- Premature Ejaculation
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00537459
- Locations
- 🇮🇪
GSK Investigational Site, Belfast, Ireland
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
Phase 1
Completed
- Conditions
- Neoplasms, Colorectal
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00536809
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Phase 1
Completed
- Conditions
- Hypertension
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00537043
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT00536835
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Depressive Disorder and Anxiety Disorders
- Interventions
- Drug: GSK163090 capsule, fastedDrug: GSK163090 Tablet, fastedDrug: GSK163090 Tablet, fed
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00536679
- Locations
- 🇩🇪
GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany
Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.
Phase 1
Withdrawn
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00536497
A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00534872
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Phase 4
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: CervarixBiological: Engerix-B
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34412
- Registration Number
- NCT00534638
- Locations
- 🇫🇮
GSK Investigational Site, Turku, Finland
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age
Phase 3
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Biological: SynflorixBiological: Infanrix hexaBiological: Rotarix
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 230
- Registration Number
- NCT00533507
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan Hsien, Taiwan
Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]Biological: GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]Biological: Fluarix [NH 2007/08 season]Biological: Fluarix [NH 2006/07 season]
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1596
- Registration Number
- NCT00532298
- Locations
- 🇳🇴
GSK Investigational Site, Stavanger, Norway
© Copyright 2025. All Rights Reserved by MedPath